Overcoming β-lactam resistance in Gram-negative pathogens

Future Medicinal Chemistry

Volumn 8, Issue 9, 2016, Pages 921-924

  Bush, Karen ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

aminoglycosides; tetracyclines; lactam; lactamase; lactamase inhibitor

Indexed keywords

BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; ANTIINFECTIVE AGENT; BETA LACTAM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; HUMAN; KLEBSIELLA PNEUMONIAE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; REVIEW; CHEMISTRY; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; PATHOGENICITY;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMS; GRAM-NEGATIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84975706564     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc-2016-0076     Document Type: Review

References (21)

1. Bush K, Craig WA, Dalie J American Society for Microbiology et al. 50 Years of ICAAC: 1961-2010. Contributions to Science. Washington, DC, USA (2010).
2. Bush K. Carbapenemases: partners in crime. J. Global Antimicrob. Resist. 1(1), 7-16 (2013).
3. Mathai D, Jones RN, Pfaller MA, America SPGN. Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1, 510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America). Diagn. Microbiol. Infect. Dis. 40(3), 129-136 (2001).
4. Sahm DF, Critchley IA, Kelly LJ et al. Evaluation of current activities of fluoroquinolones against Gram-negative bacilli using centralized in vitro testing and electronic surveillance. Antimicrob. Agents Chemother. 45(1), 267-274 (2001).
5. Farrell DJ, Sader HS, Flamm RK, Jones RN. Ceftolozane/ tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Int. J. Antimicrob. Agents 43(6), 533-539 (2014).
6. Sader HS, Castanheira M, Flamm RK, Mendes RE, Farrell DJ, Jones RN. Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010-2013). Diagn. Microbiol. Infect. Dis. 83(2), 183-186 (2015).
7. Zhao SY, Zhang J, Zhang YL et al. Epidemiology and risk factors for faecal extended-spectrum beta-lactamaseproducing Enterobacteriaceae (ESBL-E) carriage derived from residents of seven nursing homes in western Shanghai, China. Epidemiol. Infect. 144(4), 695-702 (2016).
8. Yong D, Toleman MA, Giske CG et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob. Agents Chemother. 53(12), 5046-5054 (2009).
9. Biedenbach D, Bouchillon S, Hackel M et al. Dissemination of NDM metallo-?-lactamase genes among clinical isolates of Enterobacteriaceae collected during the SMART global surveillance study from 2008 to 2012. Antimicrob. Agents Chemother. 59 826-830 (2015).
10. Veleba M, Schneiders T. Tigecycline resistance can occur independently of the ramA gene in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 56(8), 4466-4467 (2012).
11. Liu YY, Wang Y, Walsh TR et al. Emergence of plasmidmediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect. Dis. 16(2), 161-168 (2016).
12. Jayol A, Nordmann P, Desroches M, Decousser JW, Poirel L. Acquisition of broad-spectrum cephalosporin resistance leading to colistin resistance in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 60(5), 3199-3201 (2016).
13. Bush K. Investigational agents for the treatment of Gramnegative bacterial infections: a reality check. ACS Infect. Dis. 1(11), 509-511 (2015).
14. Berrazeg M, Jeannot K, Enguéné VYN et al. Mutations in ß-lactamase AmpC increase resistance of Pseudomonas aeruginosa isolates to antipseudomonal cephalosporins. Antimicrob. Agents Chemother. 59(10), 6248-6255 (2015).
15. Tomayko JF, Rex JH, Tenero DM, Goldberger M, Eisenstein BI. The challenge of antimicrobial resistance: new regulatory tools to support product development. Clin. Pharmacol. Therapeut. 96(2), 166-168 (2014).
16. Budzikiewicz H. Siderophore-antibiotic conjugates used as trojan horses against Pseudomonas aeruginosa. Curr. Topics Med. Chem. 1(1), 73-82 (2001).
17. Kohira N, West J, Ito A et al. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenemresistant strains. Antimicrob. Agents Chemother. 60(2), 729-734 (2016).
18. Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Quale J. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob. Agents Chemother. 59(3), 1802-1805 (2015).
19. Garcia-Salguero C, Rodriguez-Avial I, Picazo JJ, Culebras E. Can plazomicin alone or in combination be a therapeutic option against carbapenem-resistant Acinetobacter baumannii? Antimicrob. Agents Chemother. 59(10), 5959-5966 (2015).
20. Livermore DM, Mushtaq S, Warner M et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J. Antimicrob. Chemother. 66(1), 48-53 (2011).
21. Mensa B, Howell GL, Scott R, Degrado WF. Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16. Antimicrob. Agents Chemother. 58(9), 5136-5145 (2014).